Investigated for treating COVID-19.
Until more data become available, emapalumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Emapalumab-Lzsg is a biosimilar to Emapalumab
- TRADE NAME: Gamifant (Novimmune)
- INDICATIONS: Adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
- CLASS: Anti-interferon-gamma (IFNγ) monoclonal antibody, Covid-19 putative drug, Monoclonal antibody
- HALF-LIFE: ~22 days
- FDA APPROVAL DATE: 11/20/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: There are no available data in pregnant women to inform a drug-associated risk of adverse developmental outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 05/23/2024
